When will experimental coronavirus drugs will be ready for the clinic?

newscientistcorona
Credit: Jason Raish

Is there hope that something will be available soon to help us fight this virus, known as SARS-CoV-2? Here’s a look at what’s on tap and how soon it could be ready.

Remdesivir

Timeline: First data could come in April

Remdesivir, an antiviral medicine that failed as an Ebola treatment, was initially developed to work against a different coronavirus. There’s some evidence that it benefits Covid-19 patients.

Arthritis drugs

Timeline: Data could be available by summer; drugs available now

Drugs against autoimmune diseases like rheumatoid arthritis work by tamping down the immune system. This could, ironically, be useful against in Covid-19, because the SARS-CoV-2 virus can make the body overreact, causing what’s called a “cytokine storm,” damaging the body.

Related article:  CRISPR treatment for rare genetic eye disorder gains FDA study approval

Vaccines

Timeline: Late 2021, possibly many years

There is one approach that could deliver a vaccine faster than others: It uses messenger RNA to make cells produce proteins that could lead to immunity. This approach has never been used in a widely available vaccine. The biotech Moderna is in the lead here, but others, such as BioNTech, working with Pfizer, are working on a similar approach. It could take 18 months to be sure that approach works and is broadly safe.

Read the original post

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend